NCT06786455View on ClinicalTrials.gov

Pharmacokinetics, Pharmacodynamics, Safety, and Preliminary Efficacy of Subcutaneous Injection of SHR-1905 in Adolescent Asthmatic Subjects - an Open-label, Single-dose Phase II Clinical Study

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

January 23, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Adolescent Asthma
Interventions
DRUG

SHR-1905 Injection

SHR-1905 Injection,medium dose, administered by subcutaneous injection;

Trial Locations (1)

510030

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou

All Listed Sponsors
lead

Guangdong Hengrui Pharmaceutical Co., Ltd

INDUSTRY

NCT06786455 - Pharmacokinetics, Pharmacodynamics, Safety, and Preliminary Efficacy of Subcutaneous Injection of SHR-1905 in Adolescent Asthmatic Subjects - an Open-label, Single-dose Phase II Clinical Study | Biotech Hunter | Biotech Hunter